Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
686.2 INR | +0.80% | +0.73% | +25.73% |
Apr. 25 | Jubilant Pharmova Subsidiary's Canadian Manufacturing Unit Gets Five Observations from US FDA | MT |
Apr. 17 | Jubilant Pharmova Unit Gets VAI Status for Roorkee, India Facility | MT |
Sales 2022 | 61.3B 735M | Sales 2023 | 62.82B 753M | Capitalization | 44.42B 532M |
---|---|---|---|---|---|
Net income 2022 | 4.14B 49.61M | Net income 2023 | -610M -7.31M | EV / Sales 2022 | 1.37 x |
Net Debt 2022 | 22.03B 264M | Net Debt 2023 | 26.44B 317M | EV / Sales 2023 | 1.13 x |
P/E ratio 2022 |
14.9
x | P/E ratio 2023 |
-72.8
x | Employees | 5,778 |
Yield 2022 |
1.29% | Yield 2023 |
1.79% | Free-Float | 36.33% |
1 day | +0.80% | ||
1 week | +0.73% | ||
Current month | +20.69% | ||
1 month | +19.60% | ||
3 months | +18.98% | ||
6 months | +79.83% | ||
Current year | +25.73% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 46 | 17-05-22 | |
Chief Executive Officer | 37 | 17-05-22 | |
Arvind Chokhany
DFI | Director of Finance/CFO | 52 | 21-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 67 | 81-12-31 | |
Chairman | 71 | 78-06-20 | |
Chief Executive Officer | 46 | 17-05-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 4 M€ | -4.41% | - | |
0.00% | 34 M€ | +2.14% | - | |
0.00% | 117 M€ | +1.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 686.2 | +0.80% | 26 335 |
24-04-26 | 680.7 | +0.60% | 13,544 |
24-04-25 | 676.6 | -0.86% | 24,536 |
24-04-24 | 682.6 | -0.31% | 10,440 |
24-04-23 | 684.7 | +0.51% | 30,129 |
Delayed Quote Bombay S.E., April 29, 2024 at 06:00 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+25.73% | 1.3B | |
+25.83% | 661B | |
+26.67% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+14.79% | 231B | |
+5.33% | 200B | |
-8.83% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- JUBLPHARMA Stock